The DOI matches its Crossref record.
Preclinical pharmacological profile of the selective 5-HT1Freceptor agonist lasmiditan
Open accessAbstract
Introduction: Lasmiditan (also known as COL-144 and LY573144; 2,4,6-trifluoro- N-[6-[(1-methylpiperidin-4-yl)carbonyl]pyridin-2yl]benzamide) is a high-affinity, highly selective serotonin (5-HT) 5-HT 1F receptor agonist. Results: In vitro binding studies show a K i value of 2.21 nM at the 5-HT 1F receptor, compared with K i values of 1043 nM and 1357 nM at the 5-HT 1B and 5-HT 1D receptors, respectively, a selectivity ratio greater than 470-fold. Lasmiditan showed higher selectivity for the 5-HT 1F receptor relative to other 5-HT 1 receptor subtypes than the first generation 5-HT 1F receptor agonist LY334370. Unlike the 5-HT 1B/1D receptor agonist sumatriptan, lasmiditan did not contract rabbit saphenous vein rings, a surrogate assay for human coronary artery constriction, at concentrations up to 100 µM. In two rodent models of migraine, oral administration of lasmiditan potently inhibited markers associated with electrical stimulation of the trigeminal ganglion (dural plasma protein extravasation, and induction of the immediate early gene c-Fos in the trigeminal nucleus caudalis). Conclusions: Lasmiditan presents a unique pyridinoyl-piperidine scaffold not found in any other antimigraine class. Its chemical structure and pharmacological profile clearly distinguish it from the triptans. The potency and selectivity of lasmiditan make it ideally suited to definitively test the involvement of 5-HT 1F receptors in migraine headache therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Pathophysiology of migraine: a disorder of sensory processing
Goadsby, P. J., Holland, P. R., Martins-Oliveira, M., Hoffmann, J., Schankin, C., & Akerman, S. (2017) · Physiological Reviews · doi:10.1152/physrev.00034.2015 · Cited by 1,998
The Concise Guide to PHARMACOLOGY 2013/14: G Protein‐Coupled Receptors
Alexander, S. P. H., Benson, H. E., Faccenda, E., Pawson, A. J., Sharman, J. L., Spedding, M., Peters, J. A., Harmar, A. J., & Collaborators, C. (2013) · British Journal of Pharmacology · doi:10.1111/bph.12445 · Cited by 556
Lasmiditan is an effective acute treatment for migraine: A phase 3 randomized study
Kuca, B., Silberstein, S. D., Wietecha, L., Berg, P. H., Dozier, G., Lipton, R. B., on behalf of the COL MIG-301 Study Group, COL MIG-301 Study Group, Adams, M., Alftine, C., et al. (2018) · Neurology · doi:10.1212/wnl.0000000000006641 · Cited by 270
Barnes, N. M., Ahern, G. P., Becamel, C., Bockaert, J., Camilleri, M., Chaumont-Dubel, S., Claeysen, S., Cunningham, K. A., Fone, K. C., Gershon, M., et al. (2021) · Pharmacological Reviews · doi:10.1124/pr.118.015552 · Cited by 263
Self-citation
Metadata
- Authors
- Nelson, D. L., Phebus, L. A., Johnson, K. W., Wainscott, D. B., Cohen, M. L., Calligaro, D. O., & Xu, Y.-C.
- Venue
- Cephalalgia
- Publisher
- SAGE Publications
- Published
- 2010-06-15
- Volume
- 30
- Issue
- 10
- Pages
- 1159-1169
- ISSN
- 0333-1024 (ISSN-L)
- 1468-2982
- OpenAlex
- W2125197474
- Cited by
- 211
- References
- 0
- FWCI
- 6.58
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Preclinical pharmacological profile of the selective 5-HT1Freceptor agonist lasmiditan. https://app.cochat.ai/papers/10.1177/0333102410370873
- The paper
- Nelson, D. L., Phebus, L. A., Johnson, K. W., Wainscott, D. B., Cohen, M. L., Calligaro, D. O., & Xu, Y.-C. (2010). Preclinical pharmacological profile of the selective 5-HT1Freceptor agonist lasmiditan. Cephalalgia. https://doi.org/10.1177/0333102410370873
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.